Skip to content

Clinical Observation of Yinqiao Yin Combined with Antibiotics in the Treatment of Klebsiella pneumoniae Pneumonia

Clinical Observation of Yinqiao Yin Combined with Antibiotics in the Treatment of Klebsiella pneumoniae Pneumonia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001545
Enrollment
Unknown
Registered
2026-06-20
Start date
2026-03-26
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Klebsiella pneumoniae pneumonia (KP pneumonia)

Interventions

Experimental Group:The herbal formula Qiguiyin Decoction (composed of 60g of Astragalus membranaceus, 15g of Angelica sinensis, 15g of Honeysuckle, 10g of Artemisia annua, and 10g of Polygonum cuspida
Control Group:Symptomatic treatment

Sponsors

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Meets the diagnostic criteria for KP pneumonia in both traditional Chinese medicine and Western medicine as outlined above; 2) Age =18 years old, gender; 3) Signed the informed consent form and agreed to participate in this clinical trial.

Exclusion criteria

Exclusion criteria: 1) Mechanically ventilated patients; 2) Patients with severe pneumonia, COVID-19, or other viral pneumonia; 3) Patients with a history of organ transplantation, cancer, chronic organ failure, autoimmune diseases, pulmonary fibrosis, or tuberculosis; 4) Patients with coagulation disorders or in end-stage or terminal states due to other severe illnesses; 5) Patients with contraindications or allergies to the drugs used in this study; 6) Patients with mental disorders who are unable to cooperate; 7) Pregnant or breastfeeding women; 8) Patients currently participating in or who have participated in other clinical trials within the past month; 9) Patients using similar traditional Chinese medicine (TCM) formulations.

Design outcomes

Primary

MeasureTime frame
Time to recovery to pre-pneumonia condition;

Secondary

MeasureTime frame
Inflammatory Response Indicators;Pathogen clearance rate;Colony Forming Unit Change;The time required for fever reduction.;14-day clinical rate of severe cases;28-day mortality rate;Readmission rate within 60 days after discharge;

Countries

China

Contacts

Public ContactSun Hongyuan

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Sunhongyuan12@163.com18222521358

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026